| 23.59 0.08 (0.34%) | 11-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.93  |
1-year : | 32.63 |
| Resists | First : | 23.92 |
Second : | 27.93 |
| Pivot price | 22.55 |
|||
| Supports | First : | 21.9 |
Second : | 20.65 |
| MAs | MA(5) : | 23.13 |
MA(20) : | 22.21 |
| MA(100) : | 20.92 |
MA(250) : | 22.05 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 91.4 |
D(3) : | 85 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 26.57 | Low : | 19.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CPRX ] has closed below upper band by 17.7%. Bollinger Bands are 73.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.92 - 24.01 | 24.01 - 24.08 |
| Low: | 23.29 - 23.4 | 23.4 - 23.5 |
| Close: | 23.42 - 23.57 | 23.57 - 23.71 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Mon, 24 Nov 2025
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - GlobeNewswire
Mon, 24 Nov 2025
Catalyst Pharmaceuticals (Nasdaq: CPRX) at BofA CNS Therapeutics Conference Dec. 8 - Stock Titan
Wed, 19 Nov 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX) Ranks 304 on 2025 Deloitte Technology Fast 500 - Stock Titan
Thu, 13 Nov 2025
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Wed, 05 Nov 2025
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 123 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 87.2 (%) |
| Shares Short | 7,920 (K) |
| Shares Short P.Month | 9,630 (K) |
| EPS | 1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.46 |
| Profit Margin | 37.6 % |
| Operating Margin | 44.6 % |
| Return on Assets (ttm) | 17.7 % |
| Return on Equity (ttm) | 27.5 % |
| Qtrly Rev. Growth | 15.3 % |
| Gross Profit (p.s.) | 3.91 |
| Sales Per Share | 4.7 |
| EBITDA (p.s.) | 2.41 |
| Qtrly Earnings Growth | 20 % |
| Operating Cash Flow | 235 (M) |
| Levered Free Cash Flow | 181 (M) |
| PE Ratio | 13.79 |
| PEG Ratio | 0 |
| Price to Book value | 3.15 |
| Price to Sales | 5.01 |
| Price to Cash Flow | 12.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|